Commitments and Contingencies	3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of March 31, 2026, the Company had non-cancellable purchase commitments amounting to $186,437, of which $22,579 related to non-utilization fees and minimum purchase requirements for supply purchased from contract manufacturers and $163,858 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen. Capital Commitments The Company had capital commitments amounting to $22,925 for the acquisition of property, plant and equipment as of March 31, 2026, related to various facilities across the globe. Co-Development Funding Commitment Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1.25 billion. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of March 31, 2026, the Company’s remaining co-development funding commitment was $72,346. Funding Commitment The Company had committed capital related to equity investments in the amount of $15,056. As of March 31, 2026, the remaining capital commitment was $4,406 and is expected to be paid from time to time over the investment period.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2026

Commitments and Contingencies Disclosure [Abstract]

Purchase Commitments

As of March 31, 2026, the Company had non-cancellable purchase commitments amounting to $186,437, of which $22,579 related to non-utilization fees and minimum purchase requirements for supply purchased from contract manufacturers and $163,858 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.

Capital Commitments

The Company had capital commitments amounting to $22,925 for the acquisition of property, plant and equipment as of March 31, 2026, related to various facilities across the globe.

Co-Development Funding Commitment

Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1.25 billion. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of March 31, 2026, the Company’s remaining co-development funding commitment was $72,346.

Funding Commitment

The Company had committed capital related to equity investments in the amount of $15,056. As of March 31, 2026, the remaining capital commitment was $4,406 and is expected to be paid from time to time over the investment period.